Immunoregulatory activity by daucosterol, a β-sitosterol glycoside, induces protective Th1 immune response against disseminated Candidiasis in mice

被引:129
作者
Lee, Jue-Hee
Lee, Ju Young
Park, Ji Hye
Jung, Hye Sil
Kim, Ju Sun
Kang, Sam Sik
Kim, Yeong Shik
Han, Yongmoon
机构
[1] Dongduk Womens Univ, Coll Pharm, Dept ImmunoMicrobiol, Seoul 136714, South Korea
[2] Seoul Natl Univ, Coll Pharm, Inst Nat Prod Res, Seoul 110460, South Korea
关键词
daucosterol; Candida albicans; disseminated candidiasis; anti-CD4+; anti-IFN gamma; Th1-immune response;
D O I
10.1016/j.vaccine.2007.01.108
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
In the present study, we investigated immunomodulatory effect of daucosterol, a beta-sitosterol glycoside, against disseminated candidiasis caused by Candida albicans. Results showed that direct interaction of daucosterol with C. albicans yeast cells resulted in no growth-inhibition by in vitro susceptibility analysis. In contrast, mice given daucosterol (DS) intraperitoneally before intravenous challenge with live C. albicans yeast cells survived longer than DS-untreated control mice against disseminated candidiasis (P < 0.05). By assessment of the fungal CFU in kidneys, DS-treated mice before the challenge developed about 81% fewer kidney CFU than untreated controls. This protection was removable by pretreatment of mice with anti-CD4+ antibody before the DS-treatment and challenge with the yeast. However, the protection was transferable by the CD4+ T cells from DS-treated mice not infected with the yeast. ELISA analysis revealed there were predominant production of IFN gamma and IL-2 cytokines as compared to IL-4, and IL-10 productions in DS-treated mice. By treatment of DS-given mice with anti-mouse IFN gamma, the protection was also abolished. Our studies show that DS protects mice against disseminated candidiasis by the CD4+ Th1 immune response. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3834 / 3840
页数:7
相关论文
共 31 条
[1]
AHN EM, 1988, AGR CHEM BIOTECHNOL, V41, P486
[2]
BODY GP, 1988, J HOSP INFECT S, V11, P411
[3]
Boulic P.J.D., 1996, INT J IMMUNOPHARMACO, V18, P693
[4]
Calderone RA, 2003, CANDIDA CANDIDOSIS, P243
[5]
ROLE OF CD4+ LYMPHOCYTES IN RESISTANCE TO MUCOSAL CANDIDIASIS [J].
CANTORNA, MT ;
BALISH, E .
INFECTION AND IMMUNITY, 1991, 59 (07) :2447-2455
[6]
INVASIVE CANDIDA INFECTIONS - EVOLUTION OF A FUNGAL PATHOGEN [J].
EDWARDS, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (15) :1060-1062
[7]
Berberine synergy with amphotericin B against disseminated candidiasis in mice [J].
Han, Y ;
Lee, JH .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (03) :541-544
[8]
Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody [J].
Han, Y ;
Riesselman, MH ;
Cutler, JE .
INFECTION AND IMMUNITY, 2000, 68 (03) :1649-1654
[9]
HAN Y, 2003, YAKHAK HOEJI, V47, P190
[10]
Ginkgo terpene component has an anti-inflammatory effect on Candida albicans-caused arthritic inflammation [J].
Han, YM .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2005, 5 (06) :1049-1056